Ahead of ASCO, Corbus is providing updated data today on its Nectin-4 ADC in cervical and head and neck cancer - and has seen that response rate appears to be directly related to HPV status
- May 26
- 1 min read
In 2L cervical cancer, the company saw a confirmed ORR of 34.4% (n=70), In the highest dose used in 2L oropharyngeal squamous cell carcinoma, a subset of head and neck patients whose cancers are primarily driven by HPV, Corbus saw a confirmed ORR of 42.9% (n=21). CEO Yuval Cohen walks us through his analysis of the data.
.png){kind=logo}